Asset profile
GR1803
Multispecific antibody
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2029-03.
NCT07102706: The study assigned participants sequentially to different GR1803 doses without randomization, blinding, or a control group. Its primary endpoint was dose-limiting toxicity over 52 weeks, but the registry does not report whether this endpoint was met.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GR1803: this drug | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Teclistamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| BCD-248 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| CM336 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| F182112 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| TQB2934 | Phase 3 | Multispecific antibody | BCMA x CD3 | ||
| YKST02 | Phase 2 | Multispecific antibody | BCMA x CD3 | ||
| REGN5459 | Phase 1/2 | Multispecific antibody | BCMA x CD3 | ||
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.